In the context of cancer, autoantibodies can be produced in response to tumor-associated antigens (TAAs). These antigens are proteins that are abnormally expressed or modified in cancer cells. The presence of autoantibodies against these TAAs can sometimes be detected before clinical symptoms of cancer appear, making them potential biomarkers for early cancer detection.